Axon Enterprise, Inc. (NASDAQ:AXON) CEO Sells $18,928,911.98 in Stock

Axon Enterprise, Inc. (NASDAQ:AXON) CEO Patrick W. Smith sold 47,314 shares of the firm’s stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $400.07, for a total transaction of $18,928,911.98. Following the completion of the sale, the chief executive officer now directly owns 2,983,802 shares in the company, valued at approximately $1,193,729,666.14. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Axon Enterprise Stock Performance

NASDAQ:AXON opened at $421.80 on Friday. Axon Enterprise, Inc. has a 1-year low of $192.63 and a 1-year high of $422.33. The firm has a 50 day simple moving average of $363.44 and a 200-day simple moving average of $322.68. The firm has a market cap of $31.88 billion, a PE ratio of 123.33, a P/E/G ratio of 10.84 and a beta of 0.94. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.88 and a quick ratio of 2.52.

Axon Enterprise (NASDAQ:AXON) last posted its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.18. The company had revenue of $504.00 million during the quarter, compared to the consensus estimate of $478.35 million. Axon Enterprise had a net margin of 16.06% and a return on equity of 9.34%. The company’s quarterly revenue was up 34.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.80 EPS. On average, equities analysts expect that Axon Enterprise, Inc. will post 1.79 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. Needham & Company LLC restated a “buy” rating and issued a $400.00 price target on shares of Axon Enterprise in a research note on Wednesday, August 7th. Jefferies Financial Group started coverage on shares of Axon Enterprise in a research note on Wednesday, July 17th. They set a “buy” rating and a $385.00 price target for the company. Northland Securities lifted their target price on Axon Enterprise from $330.00 to $365.00 and gave the company an “outperform” rating in a research note on Thursday, August 8th. Bank of America began coverage on shares of Axon Enterprise in a research note on Wednesday, July 17th. They set a “buy” rating and a $380.00 price target on the stock. Finally, Barclays upped their price objective on Axon Enterprise from $381.00 to $387.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. Two equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $365.38.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AXON. Dorsey Wright & Associates raised its position in Axon Enterprise by 0.3% in the second quarter. Dorsey Wright & Associates now owns 14,053 shares of the biotechnology company’s stock valued at $4,135,000 after purchasing an additional 39 shares during the period. Avantax Advisory Services Inc. raised its holdings in shares of Axon Enterprise by 0.8% during the first quarter. Avantax Advisory Services Inc. now owns 5,302 shares of the biotechnology company’s stock worth $1,659,000 after purchasing an additional 40 shares during the period. Brookstone Capital Management raised its stake in Axon Enterprise by 5.1% during the first quarter. Brookstone Capital Management now owns 839 shares of the biotechnology company’s stock worth $263,000 after acquiring an additional 41 shares during the period. CWM LLC lifted its holdings in shares of Axon Enterprise by 1.5% in the 2nd quarter. CWM LLC now owns 2,820 shares of the biotechnology company’s stock worth $830,000 after purchasing an additional 43 shares during the last quarter. Finally, Wealthspan Partners LLC lifted its stake in Axon Enterprise by 4.9% in the second quarter. Wealthspan Partners LLC now owns 965 shares of the biotechnology company’s stock valued at $284,000 after buying an additional 45 shares during the last quarter. Institutional investors and hedge funds own 79.08% of the company’s stock.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.